Description

ISOFAIR 40 MG

Indications

ISOFAIR 40 MG is primarily indicated for the treatment of moderate to severe plaque psoriasis in adults. It is also used in the management of psoriatic arthritis, providing relief from joint pain and inflammation associated with this condition. Additionally, ISOFAIR may be prescribed for other dermatological disorders as determined by a healthcare professional, particularly when conventional therapies have failed or are not suitable for the patient.

Mechanism of Action

ISOFAIR contains the active ingredient Apremilast, which is a phosphodiesterase 4 (PDE4) inhibitor. By inhibiting PDE4, ISOFAIR increases the levels of cyclic adenosine monophosphate (cAMP) within cells. Elevated cAMP levels lead to a reduction in the production of pro-inflammatory cytokines, which play a significant role in the inflammatory processes associated with psoriasis and psoriatic arthritis. This mechanism helps to modulate the immune response and reduce inflammation, leading to an improvement in the symptoms of these conditions.

Pharmacological Properties

ISOFAIR is characterized by its oral bioavailability and is rapidly absorbed following administration. The peak plasma concentration is typically reached within 2 hours. The drug is extensively metabolized in the liver, primarily through the cytochrome P450 enzyme system, and has a half-life of approximately 6 to 9 hours. The pharmacokinetics of ISOFAIR can be affected by factors such as age, weight, and hepatic function, necessitating careful consideration during prescribing.

Contraindications

ISOFAIR is contraindicated in patients with a known hypersensitivity to Apremilast or any of the excipients in the formulation. It should also be avoided in individuals with severe renal impairment, as the safety and efficacy of the drug in this population have not been established. Caution is advised when considering ISOFAIR for patients with a history of depression or suicidal thoughts, as these conditions may be exacerbated during treatment.

Side Effects

Common side effects associated with ISOFAIR include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Other reported adverse effects may include headache, fatigue, and upper respiratory tract infections. Serious side effects, although less common, can include severe depression, suicidal ideation, and allergic reactions. Patients should be monitored closely for any signs of mood changes or unusual behavior during treatment.

Dosage and Administration

The recommended starting dose of ISOFAIR is 10 mg taken orally once daily for the first week, followed by an increase to 20 mg once daily for the second week. After this initial titration period, the dose is typically increased to 40 mg once daily. ISOFAIR can be taken with or without food, but it is essential to adhere to the prescribed dosing schedule for optimal therapeutic effects. In cases of missed doses, patients should take the missed dose as soon as they remember, unless it is close to the time of the next scheduled dose; in such cases, the missed dose should be skipped.

Interactions

ISOFAIR may interact with other medications, particularly those that are metabolized by the cytochrome P450 enzyme system. Caution should be exercised when co-administering ISOFAIR with strong CYP450 inducers or inhibitors, as these can affect the plasma levels of Apremilast. Additionally, patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before initiating treatment with ISOFAIR, a thorough medical history should be obtained, particularly regarding any history of depression or mood disorders. Regular monitoring for signs of depression or suicidal thoughts is recommended during treatment. Patients with a history of renal impairment should be closely monitored, and dosage adjustments may be necessary based on renal function. It is also advisable for patients to avoid live vaccines during treatment due to the potential impact on the immune system.

Clinical Studies

Clinical studies have demonstrated the efficacy of ISOFAIR in reducing the severity of psoriasis and improving the quality of life for patients suffering from psoriatic arthritis. In randomized controlled trials, patients receiving ISOFAIR showed significant improvements in the Psoriasis Area and Severity Index (PASI) scores compared to placebo groups. Additionally, long-term studies have indicated that ISOFAIR maintains its effectiveness over extended periods, with a favorable safety profile. These findings support the use of ISOFAIR as a viable treatment option for patients with moderate to severe psoriasis and psoriatic arthritis.

Conclusion

ISOFAIR 40 MG represents a significant advancement in the management of moderate to severe plaque psoriasis and psoriatic arthritis. Its unique mechanism of action as a PDE4 inhibitor allows for effective modulation of the inflammatory response, leading to improved clinical outcomes. While ISOFAIR is generally well-tolerated, it is essential for healthcare providers to monitor patients for potential side effects and interactions with other medications. With appropriate use, ISOFAIR can provide substantial relief for patients suffering from these challenging conditions, enhancing their overall quality of life.